Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Earnings for Corvus Pharmaceuticals, Inc. (CRVS)
Earnings in 2023 (TTM): $-27,029,000
According to Corvus Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-27,029,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Corvus Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-27,029,000 | $-27,029,000 |
| 2022 | $-41,307,000 | $-50,049,000 |
| 2021 | $-43,241,000 | $-38,200,000 |
| 2020 | $-5,995,000 | $-4,823,000 |
| 2019 | $-46,672,000 | $-43,747,000 |
| 2018 | $-46,939,000 | $-46,939,000 |
| 2017 | $-55,663,000 | $-55,663,000 |
| 2016 | $-36,375,000 | $-36,375,000 |
| 2015 | $-31,335,000 | $-31,335,000 |
| 2014 | $-175,636 | $-175,636 |